Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial
Health Technology Assessment · 2025
DOI: 10.3310/hbfc1953 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Health Technology Assessment, 2025. Verfasst von Hamish McAllister-Williams und 35 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Pramipexole, Bipolar Disorder, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.
Themen: Depression
Abstract (Originalsprache)
Background
There are limited options currently recommended in National Institute for Health and Care Excellence guidelines for the treatment of bipolar depression. Pramipexole has been shown to improve mood symptoms in two small pilot studies in such patients.
Objectives
Primary: to evaluate the clinical effectiveness of pramipexole versus placebo alongside routine mood-stabilising medications over 12 weeks in patients with treatment-resistant bipolar depression. Secondary: evaluate the impact of pramipexole on mood and anxiety, psychosocial function, cost-effectiveness, and safety and tolerability over 48 weeks.
Design
Multicentre, randomised, placebo-controlled trial of pramipexole versus placebo in addition to standard-of-care mood stabilisers. Clinicians, researchers and participants were blinded throughout the duration of the study. Pre-randomisation stage (to adjust antipsychotics or commence mood stabilisers where required) before randomisation. Weekly online assessments of mood and anxiety from randomisation to week 52, with psychosocial function, quality of life and healthcare resource utilisation assessments conducted at regular intervals.
Setting
Twenty-one National Health Service trusts and Health Boards across England and Scotland.
Participants
Patients aged 18 years and over with a diagnosis of treatment-resistant bipolar depression currently under secondary care mental health services. Aim to randomise 290 participants.
Interventions
Pramipexole or matched placebo orally once daily, titrated from 0.25 mg to maximum of 2.5 mg (salt weight) depending on efficacy and tolerability. Main outcome measures Depression – Quick Inventory for Depressive Symptomology; anxiety – Generalised Anxiety Disorder-7-item scale; psychosocial functioning – Work and Social Adjustment Scale; hypomania/mania – Altman Self-rating Scale of Mania; tolerability – Treatment Satisfaction Questionnaire for Medication; well-being and quality of life – EuroQol-5 Dimensions, five-level version, ICEpop CAPability measure for Adults and Oxford CAPabilities questionnaire-Mental Health tools.
Results
Thirty-nine participants randomised (18 to pramipexole and 21 to placebo) with 36 providing data for the primary analysis. Pramipexole led to greater reductions in depressive symptoms at 12 weeks compared to placebo [4.4 (4.8) vs. 2.1 (5.1)]: a medium-sized ( d = −0.72) but not statistically significant difference (95% confidence interval −0.4 to 6.3; p = 0.087). There were some statistically significant positive effects of pramipexole on secondary outcomes (reduction in depressive symptoms at 36 weeks, response and remission rates at trial exit, psychosocial function). Pramipexole was associated with an increased rate of hypomania/manic symptoms, but this appeared to be reduced by coadministration with an antipsychotic. General tolerability of pramipexole was good. There were significant annual gains in health-related quality of life and capability-well-being and tendency towards reduced health and social care costs.
Limitations
Small sample size and variable follow-up period due to recruitment during COVID-19 pandemic and the trial closing early. Participants limited to those in secondary care mental health services. All assessments only available in English.
Conclusions
No change in clinical practice can be recommended as there was not a significant difference between pramipexole and placebo on the primary efficacy outcome measure. However, there was evidence of positive effects of pramipexole on mood, psychosocial function and quality of life. Future work Replication in a larger population and research to investigate the impact of coadministration of antipsychotics alongside pramipexole.
Trial registration
This trial is registered as ISRCTN72151939 and EudraCT 2018-2869-18. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/154/01) and is published in full in Health Technology Assessment ; Vol. 29, No. 21. See the NIHR Funding and Awards website for further award information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
- Northern Centre for Mood Disorders, Newcastle University, Newcastle upon Tyne, UK.
- Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
- Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
- Medical University of Vienna, Vienna, Austria.
- Sheffield Health and Social Care NHS Foundation Trust, Sheffield, UK.
ORCID-Profile: Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, Victoria Bartle, Michael Berger, Chrissie Butcher, Thomas Chadwick, Emily Clare, Paul Courtney, Lyndsey Dixon, Nichola Duffelen, Tony Fouweather, William Gann, John Geddes, Sumeet Gupta, Beth Hall, Timea Helter, Paul Hindmarch, Eva-Maria Holstein, Ward Lawrence, Phil Mawson, Iain McKinnon, Adam Milne, Aisling Molloy, Abigail Moore, Richard Morriss, Anisha Nakulan, Judit Simon, Daniel Smith, Bryony Stokes-Crossley, Paul Stokes, Andrew Swain, Zoë Walmsley, Christopher Weetman, Allan H Young, Stuart Watson
Förderung
- Health Technology Assessment programme
Zitieren
APA
McAllister-Williams, H., Goudie, N., Azim, L., Bartle, V., Berger, M., Butcher, C., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Gann, W., Geddes, J., Gupta, S., Hall, B., Helter, T., Hindmarch, P., Holstein, E. M., …, & Watson, S. (2025). Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial. Health Technology Assessment. https://doi.org/10.3310/hbfc1953
Vancouver
McAllister-Williams H, Goudie N, Azim L, Bartle V, Berger M, Butcher C, et al. Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial. Health Technology Assessment. 2025. doi:10.3310/hbfc1953
BibTeX
@article{McAllisterWilliams2025,
author = {McAllister-Williams, Hamish and Goudie, Nicola and Azim, Lumbini and Bartle, Victoria and Berger, Michael and Butcher, Chrissie and Chadwick, Thomas and Clare, Emily and Courtney, Paul and Dixon, Lyndsey and Duffelen, Nichola and Fouweather, Tony and Gann, William and Geddes, John and Gupta, Sumeet and Hall, Beth and Helter, Timea and Hindmarch, Paul and Holstein, Eva-Maria and Lawrence, Ward and Mawson, Phil and McKinnon, Iain and Milne, Adam and Molloy, Aisling and Moore, Abigail and Morriss, Richard and Nakulan, Anisha and Simon, Judit and Smith, Daniel and Stokes-Crossley, Bryony and Stokes, Paul and Swain, Andrew and Walmsley, Zoë and Weetman, Christopher and Young, Allan H and Watson, Stuart},
title = {Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial},
journal = {Health Technology Assessment},
year = {2025},
doi = {10.3310/hbfc1953}
}
EUVIMED